Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 9 Feb 2005 |
| Genmab A/S, Capital Increase in Genmab as a Result of Employee Warrant Exercise | 9 Feb 2005 |
| Genmab, preliminary announcement of annual report 2004 | 8 Feb 2005 |
| Genmab, announces year end 2004 financial results | 8 Feb 2005 |
| InvestorService: Genmab A/S, to Present at 2005 Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference | 1 Feb 2005 |